Adi Zuloff-Shani

Clearmind Medicine Inc. (NASDAQ:CMND) filed a patent application for its combination therapy involving Ibogaine and N-Acylethanolamines. What Happened: The therapy was developed in collaboration with SciSparc Ltd. (NASDAQ:SPRC). It combines the psychedelic compound Ibogaine with...

Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biotech firm based in Vancouver, has been granted a new patent by the United States Patent and Trademark Office. As the company stated in a press release, this approval marks a significant milestone in Clearmind's efforts to develop...

Clearmind Medicine Inc. (CSE: CMND) (OTCPK:CMNDF) revealed Thursday promising results from two pre-clinical trials which tested suppression of alcohol consumption in mice using its novel psychedelic-based therapeutic CMND-100, whose active pharmaceutical ingredient is MEAI. The first trial...

Psychedelic-focused biotech company Clearmind Medicine Inc. (CSE:CMND) (OTC: CMNDF) has signed a collaboration agreement with SciSparc Ltd. (NASDAQ: SPRC).The two companies will explore the potential for the creation of innovative compounds in the psychedelic area. The collaboration will address,...